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ABSTRACT
Hepatocellular carcinoma (HCC) is the most common primary liver tumor
worldwide. Current medical therapy for HCC has limited efficacy. The present study
tests the hypothesis that human cerebral endothelial cell-derived exosomes carrying
elevated miR-214 (hCEC-Exo-214) can amplify the efficacy of anti-cancer drugs on
HCC cells. Treatment of HepG2 and Hep3B cells with hCEC-Exo-214 in combination
with anti-cancer agents, oxaliplatin or sorafenib, significantly reduced cancer cell
viability and invasion compared with monotherapy with either drug. Additionally,
the therapeutic effect of the combination therapy was detected in primary tumor
cells derived from patients with HCC. The ability of hCEC-Exo-214 in sensitizing HCC
cells to anti-cancer drugs was specific, in that combination therapy did not affect
the viability and invasion of human liver epithelial cells and non-cancer primary
cells. Furthermore, compared to monotherapy with oxaliplatin and sorafenib, hCECExo-214 in combination with either drug substantially reduced protein levels of
P-glycoprotein (P-gp) and splicing factor 3B subunit 3 (SF3B3) in HCC cells. P-gp and
SF3B3 are among miR-214 target genes and are known to mediate drug resistance
and cancer cell proliferation, respectively. In conclusion, the present in vitro study
provides evidence that hCEC-Exo-214 significantly enhances the anti-tumor efficacy
of oxaliplatin and sorafenib on HCC cells.

INTRODUCTION

transplantation are curative options but are offered to a
small percentage of eligible patients [2]. Patients with
advanced liver cancer, have limited medical options
including sorafenib, which increases overall survival by
less than three months [3]. Drug resistance is often evident
within several months of initial treatment [4]. The low

Liver cancer is the fifth leading cause of cancer
death worldwide. Hepatocellular carcinoma (HCC) is
the dominant form of primary liver cancer, accounting
for 85–90% of cases [1]. Surgical resection and liver
www.oncotarget.com
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efficacy and high adverse side effect profile of currently
available therapy provide a compelling need for more
effective treatments [5].
MicroRNAs (miRNAs) are non-coding, small
regulatory RNAs that target the 3′-untranslated region (3′UTR) of mRNAs and negatively regulate gene expression
at the post-transcriptional level [6, 7]. miRNAs are key
players in cancer biology, affecting molecular pathways
involved in cell proliferation, angiogenesis, invasion,
metastasis, and apoptosis in cancer progression [8, 9].
miRNAs help mediate HCC pathogenesis [10, 11].
miR-214, specifically, appears to function as a tumor
suppressor in HCC by inhibiting cell proliferation,
invasion, angiogenesis, and metastasis [12, 13]. Downregulation of miR-214 has been detected in patients with
HCC and in HCC cell lines [14–16]. miR-214 targets
genes including hepatoma-derived growth factor (HDGF)
[17], fibroblast growth factor receptor 1 (FGFR1) [18],
β-catenin [14], and Wnt3a [19]. Upregulation of miR-214,
therefore, may have a potential therapeutic role in HCC.
However, to date, systemic delivery of RNAs, including
miRNAs, have had limited therapeutic efficacy in cancer
therapy [20].
Exosomes are cell-derived extracellular nanovesicles (~30–150 nm) found in a wide range of biofluids
and tissues [21]. They transport biologically active
molecules including proteins, lipids, DNA, and RNA as
cargo and facilitate local and long-distance intercellular
communication [22–25]. Although essentially all
eukaryotic cell types produce exosomes, emerging
evidence has shown that exosome cargos differ greatly
depending on their cell of origin [26]. Tumor cellderived exosomes are actively involved in metastatic
niche formation, cancer progression, immune function
regulation, and drug resistance [27–31]. Blood-derived
exosomes are potential diagnostic and prognostic
biomarkers for HCC [32–34]. In addition, use of
exosomes as a vehicle to carry chemo-drugs, proteins,
and miRNAs to treat cancer is being actively investigated
[35–38]. The majority of intravenously administered
exogenous exosomes are taken up by liver [39], making
the use of exosomes to treat liver cancer especially
appealing. Indeed, several studies have investigated the
effect of engineered exosomes on liver cancer [40–42].
For example, mesenchymal stem cell (MSC)-derived
exosomes carrying elevated miR-122 [43] and miR-199
[44] increase anti-cancer drug sensitivity of HCC cells to
sorafenib and doxorubicin, respectively.
We previously demonstrated that engineered
human cerebral endothelial cell-derived exosomes
carrying elevated miR-214 (hCEC-Exo-214) sensitize
ovarian cancer cells to chemotherapeutic agents [45]. In
the present study, we test the hypothesis that miR-214
enriched exosomes can enhance the effect of anti-cancer
drugs, oxaliplatin and sorafenib, on HCC cells.

www.oncotarget.com

Downregulation of miR-214 in hepatocellular
carcinoma cells
miRNAs including miR-214 are involved in
the development of HCC. We examined miR-214
expression in two HCC cell lines, HepG2 and Hep3B.
Quantitative RT-PCR analysis showed that, compared to
normal human liver epithelial cells (THLE-2), HepG2
and Hep3B cells exhibited an approximate 50 and 70%
significant reduction in miR-214 expression, respectively,
whereas miR-92 expression was upregulated in HCC
cells (Figure 1A). Additionally, we measured miR-214
levels in liver tumor tissues acquired from patients with
HCC who had undergone tumor resection. We found
that, compared to non-tumor liver tissue from the same
individuals, 3 of 5 (60%) tumor tissues showed reduced
miR-214 levels (Figure 1B). These data are consistent with
reports by others [14–16, 19, 46] and suggest that miR214 is involved in HCC.

Engineered hCEC-exosomes carrying elevated
miR-214 (hCEC-Exo-214) enhance HCC
sensitivity to anti-cancer drugs
Overexpression of miR-214 in SK-Hep1 cells
inhibits tumor cell growth [14, 17]. Using hCEC-Exo-214,
we have demonstrated that the engineered hCEC-Exo-214
sensitize ovarian cancer cells to chemotherapeutic agents
[45]. hCEC-Exo-214 were isolated from the supernatant
of hCECs transfected with a lentivector expressing premiR-214 by means of differential ultracentrifugation.
Isolated extracellular vesicles had a mean size of 104 nm
and exhibited donut-shaped morphology demonstrated by
Nanoparticle Tracking Analysis (NTA) and transmission
electron microscopy (TEM), respectively (Figure 1C and
1D). Western blot analysis revealed that these extracellular
vesicles expressed exosomal marker proteins, CD9, CD63,
and Alix (Figure 1E). Quantitative RT-PCR showed that,
compared to non-transfected hCECs, hCECs transfected
with pre-miR-214 had upregulated miR-214. hCECExo-214 had an approximately 11-fold increase in miR214 compared to naïve hCEC-Exo (Figure 1F).
hCEC-Exo-214, alone and in combination with anticancer drugs, were evaluated for their effect on HepG2
and Hep3B cells. Neither naïve hCEC-Exo nor hCECExo-214 alone at doses of 107, 108, and 109 particles/ml
affected HCC cell viability measured by the MTT assay
(Figure 2A). Oxaliplatin and sorafenib by themselves
decreased cell viability of both HepG2 and Hep3B cells in
a dose-dependent manner (Figure 2A and Supplementary
Figure 1), consistent with previous reports [47–49].
Based on the dose response data, a dose at 0.0625 μM
of oxaliplatin was selected for HepG2 and Hep3B cells,
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while a dose of 1.2 μM or 0.8 μM of sorafenib was selected
for HepG2 or Hep3B cells, respectively (Supplementary
Figure 1). Naïve hCEC-Exo and hCEC-Exo-214 were
evaluated to determine whether they enhanced the effect
of oxaliplatin or sorafenib on HCC viability. The MTT
analysis showed that naïve hCEC-Exo or hCEC-Exo-214
in combination with oxaliplatin or sorafenib significantly
reduced viable HepG2 and Hep3B cells in an exosomal
concentration dependent manner with the most robust
reduction at the highest concentration (109 particles/ml)

tested (Figure 2A). Importantly, compared to naïve hCECExo, hCEC-Exo-214 further significantly reduced cancer
cell viability (Figure 2A). In contrast, naïve hCEC-Exo
or hCEC-Exo-214, in combination with oxaliplatin and
sorafenib, did not significantly affect normal liver epithelial
cell viability (Supplementary Figure 2), suggesting that
the enhanced anti-cancer drug activity of combination
treatment is specific to HCC tumor cells.
Next, the effect of combination therapy on HCC
cell invasion was evaluated by means of a transwell cell

Figure 1: Characterization of miR-214 enriched exosomes. (A) Quantitative RT-PCR analysis of miR-214 and miR-92 levels in

cell lines. (B) Quantitative RT-PCR analysis of miR-214 levels in tumor and non-tumor tissue of five individual HCC patients. (C) NTA
analysis shows particle distributions of EVs isolated from culture medium of hCEC cells transfected by miR-214. (D) Representative TEM
images of exosomes isolated from naïve (hCEC-Exo) and miR-214 transfected (hCEC-Exo-214) hCEC cells. (E) Representative Western
blot images show exosomal marker proteins in supernatant (Sup) and exosomes (Exos). (F) Quantitative RT-PCR analysis shows miR-214
levels in non-transfected and transfected hCECs, and in exosomes isolated from naïve (hCEC-Exo) and miR-214 transfected (hCECExo-214) hCEC cells. All mRNAs were normalized with U6 snRNA. Data are presented as mean ± SEM. N = 3. #P < 0.05, §P < 0.01, *P
< 0.001.
www.oncotarget.com
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invasion assay [50, 51]. The transwell assay analysis
showed that neither naïve hCEC-Exo nor hCEC-Exo-214
alone significantly reduced cell invasion. However, naïve
hCEC-Exo or hCEC-Exo-214, in combination with
oxaliplatin or sorafenib significantly reduced HepG2
and Hep3B cell invasion (Figure 2B). Compared with
naïve hCEC-Exo, hCEC-Exo-214, in combination with
oxaliplatin or sorafenib, had a more robust effect on
reduction of HepG2 and Hep3B cell invasion (Figure 2B).
Collectively, these data indicate that hCEC-Exo
enhance the anti-HCC effect of oxaliplatin and sorafenib,
and that engineered hCEC-Exo-214 have a more potent
anti-HCC effect than naïve hCEC-Exo.

exosome-primed cells. Compared to non-primed HCC
cells, oxaliplatin or sorafenib significantly reduced cell
viability of HepG2 and Hep3B cells primed with hCECExo-214, although the reduction was marginal (Figure
4A). Considering that cell viability was assayed 6 days
after hCEC-Exo-214 priming, the marginal yet significant
difference observed (Figure 4A) is of note. However,
oxaliplatin or sorafenib more profoundly reduced HepG2
and Hep3B cell invasion in hCEC-Exo-214 primed HCC
cells (Figure 4B). Collectively, these priming data suggest
that priming HCC cells with hCEC-Exo-214 enhances the
anti-cancer drug efficacy of oxaliplatin and sorafenib.

The combination of hCEC-Exo-214 with
anti-cancer therapy reduces protein levels of
P-glycoprotein and splicing factor 3B subunit 3
in HCC cells

Engineered hCEC-Exo-214 sensitize patient
tumor-derived primary cells to anti-cancer drugs
The effect of hCEC-Exo-214, in combination with
oxaliplatin or sorafenib, was evaluated in six patientderived tumor cells. Patient 1 had a hepatocellular
adenoma (HCA) which is a benign liver tumor. Patients
2–6 had HCC. Compared to anti-cancer drugs alone,
naïve hCEC-Exo or hCEC-Exo-214, in combination with
oxaliplatin or sorafenib, significantly reduced the viability
of patient-derived tumor cells from all three individual
patients with HCC (patients 2–4) tested. hCEC-Exo-214
were significantly more effective than naïve hCEC-Exo
in sensitizing HCC to anti-tumor drugs (Figure 3A).
Sorafenib is the FDA approved, first-line treatment for
advanced hepatocellular carcinoma. We thus, examined
the effect of hCEC-Exo-214 in combination with sorafenib
on cell invasion of patient tumor-derived primary cells.
The combination treatment significantly inhibited primary
cell invasion compared with sorafenib treatment alone
(Figure 3B). Interestingly, the significant effects of the
combination treatment on cell viability and invasion were
not detected in primary tumor cells from the patient with
HCA (Figure 3A and 3B).
These data suggest that the results of the
combination treatment on HepG2 and Hep3B cell lines
are more applicable to patient-derived tumor cells from
HCC patients than from the HCA patient.

P-glycoprotein (P-gp), encoded by the adenosine
triphosphate (ATP)-binding cassette subfamily B member
1 (ABCB1) gene, is one of the genes known to facilitate
HCC chemoresistance [27]. Western blot analysis
revealed that, compared to drug alone, hCEC-Exo-214
in combination with oxaliplatin or sorafenib significantly
reduced P-gp protein levels in HepG2 and Hep3B cells
(Figure 5A). The effect of the combination treatment
on reduction of P-gp appears specific because the
combination treatment did not affect levels of multidrug
resistance-associated protein 2 (MRP2) (Supplementary
Figure 3). Additionally, we found that hCEC-Exo-214 in
combination with oxaliplatin or sorafenib significantly
reduced protein levels of splicing factor 3B subunit 3
(SF3B3) (Figure 5B). SF3B3 is a putative target for miR214 as predicted by TargetScan (version 7.2, http://www.
targetscan.org) (Figure 5C). To verify whether miR-214
targets SF3B3, a dual-luciferase assay was performed.
Co-transfection with the wildtype (WT) 3′-UTR region
of SF3B3 with miR-214 mimics significantly reduced
luciferase activity to ~71.5% of that seen with a negative
control (NC). This is comparable to reduced levels of
other genes targeted by miR-214 [14, 15, 17]. In addition,
miR-214 mimics did not significantly reduce luciferase
activity when SF3B3 3′-UTR was mutated (Figure 5C).
These data suggest that miR-214 targets SF3B3 3′-UTR.
Collectively, these data suggest that reduction of P-gp and
SF3B3 proteins may contribute to the observed beneficial
effect of combination treatment on HepG2 and Hep3B
cells.

Priming with hCEC-214-Exo sensitizes HCC
cells to the anti-tumor effect of therapeutic drugs
Tumor cell-derived exosomes are essential to
metastatic niche formation, tumor development and
progression [52]. Although aforementioned data indicate
that the hCEC-Exo-214 alone did not impact HCC cell
viability and invasion, we examined whether priming
HCC cells with exosomes affects anti-cancer drug efficacy
in HCC cells. HepG2 and Hep3B cells were treated with
hCEC-Exo-214 for two days, after which culture medium
was replaced with fresh medium without hCEC-Exo-214.
Oxaliplatin or sorafenib were subsequently applied to the
www.oncotarget.com

DISCUSSION
The present study shows that naïve hCEC-Exo
and engineered hCEC-Exo-214 substantially sensitize
HCC cells to the effects of traditional anti-cancer agents.
The impact was significantly more potent with hCECExo-214 than with hCEC-Exo. The effect was seen on
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both HCC cell viability and invasion (Figure 2). The
amplified benefit of the combination therapy was observed
in multiple HCC cell lines and was also seen in primary
cancer cells from multiple patients with HCC. The effect
was present with two drugs with divergent mechanisms
of action and was specific to neoplastic tissue. These in
vitro data demonstrate, for the first time, that hCEC-Exo,
particularly exosomes carrying elevated miR-214, can
enhance the anti-tumor effect of oxaliplatin or sorafenib
against HCC.
Tumor-derived extracellular vesicles (EVs),
including exosomes, mediate cancer formation,

progression, and metastasis by facilitating communication
between the cancer niche and distal cells [53]. For
example, tumor-derived exosomes induce epithelialmesenchymal transition (EMT) [54] and chemoresistance
[55, 56]. Compared to studies using tumor-derived
EVs as biomarkers of cancer presence or progression,
investigations of exogenous exosomes as therapeutic
agents in cancer are more limited. EVs derived from
human liver stem cells suppress growth of HepG2 and
primary HCC cells [57], while EVs derived from human
bone marrow mesenchymal stem cells inhibit in vitro cell
cycle progression of several tumor cell lines, including

Figure 2: hCEC-Exo-214 sensitize HCC cells to anti-cancer drugs. (A) Cell viability of HepG2 and Hep3B cells treated with

anti-cancer drugs and exosomes. Data are representative of three independent experiments. Values are expressed as mean ± SD. N = 5.
(B and C) Representative images and quantitative data show cell invasion of HepG2 (B) and Hep3B (C) cells treated with hCEC-Exo or
hCEC-Exo-214 in combination with oxaliplatin or sorafenib. Data are presented as mean ± SEM. N = 3. #P < 0.05, §P < 0.01, *P < 0.001.
www.oncotarget.com
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HepG2, and in vivo progression of subcutaneous tumors
in SCID mice [58].
The present study shows that naïve hCEC-Exo and
engineered hCEC-Exo-214 sensitize HCC cells to the anticancer effects of sorafenib and oxaliplatin as measured
by cell viability and invasion assays (Figures 2 and 3).
These findings are further supported by priming data in
which HCC cells, pre-treated with naïve hCEC-Exo or
engineered hCEC-Exo-214, experience an enhanced antitumor effect of oxaliplatin or sorafenib. Monotherapy
with naïve hCEC-Exo or engineered hCEC-Exo-214 did
not significantly affect HCC cell viability or invasion

(Figure 4). The therapeutic effect is specific to HepG2
and Hep3B cells in that the combination therapy did not
affect the viability or invasion of the hepato-epithelial cell
line, THLE-2 (Supplementary Figure 2). Importantly, the
anti-tumor effect of the combination therapy was observed
in primary cancer cells derived from patients with HCC
but not in tumor cells derived from a patient with HCA
(Figure 3). These data suggest that the combination therapy
preferentially targets HCC cells, which is consistent with
evidence that the interaction of exosome cargo with
recipient cells is cell type dependent [59]. Taken together,
the present study suggests a potential therapeutic role for

Figure 3: The effect of the combination therapy on tumor primary cells derived from patients with liver tumor. (A)

Quantitative data from MTT assay showed the effect of hCEC-Exo or hCEC-Exo-214 in combination with oxaliplatin or sorafenib on cell
viability of primary cells derived from tumor tissues of four individual patients (Pt) with hepatocellular adenoma (HCA) or hepatocellular
adenoma (HCC). Data are presented as mean ± SD. N = 5. (B) Representative microscopic images and quantitative invasion data showed
the effect of hCEC-Exo or hCEC-Exo-214 in combination with sorafenib on cell invasion of primary cells derived from tumor tissues of
six individual patients with HCA or HCC. Values are expressed in mean ± SEM. N = 3. *P < 0.001.
www.oncotarget.com
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exosomes derived from human cerebral endothelial cells
to enhance traditional anti-cancer drug treatment in HCC.
The use of exosomes to deliver miRNAs for
treatment of HCC has been investigated. Exosomes
carrying miR-451a [41], miR-125b [42], miR-122 [43]
and miR-26 [40] suppress HCC growth. However, the
role of miR-214 in mediating cancer progression has
been investigated with inconsistent results. In one study,
miR-214 was found to have increased expression in
breast cancer tissue which contributed to cell invasion
[60, 61]. A conflicting study found decreased levels of
miR-214 in breast cancer tissue leading to increased cell
proliferation and invasion [60, 61]. In addition, miR-214
negatively regulates liver metastasis of colorectal cancer
[18], but contributes to tumor progression and metastasis
in melanoma [62]. In HCC, overexpression of miR-214
in HepG2, Hep3B, HLE, and SK-HEP-1 cells suppresses

cell growth and invasion [14, 19]. Ectopic expression
of miR-214 in SK-HEP-1 cells inhibits xenograft tumor
formation and decreases microvascular density in tumorbearing nude mice [14]. In this study, using qRT-PCR
analysis, miR-214 was found to be downregulated in
HCC cell lines and in primary patient HCC cells, which
validates reports by others [14–16]. Using multiple
experimental approaches, the present study, for the first
time, demonstrates that exosomes carrying elevated miR214 enhance anti-cancer drug sensitivity in HCC cells.
Therapeutically engineered exosomes carrying
elevated miR-214, hCEC-Exo-214, robustly and
specifically amplify anti-cancer drug efficacy in HCC cell
lines and in patient-derived HCC cells. We do not rule
out that exosomes from other cells may have comparable
activity, in this regard, but we chose to evaluate hCECExo because we found, in preliminary studies, they

Figure 4: The effect of priming HCC cells with hCEC-Exo-214 on anti-cancer drug treatment. (A) Schematic illustration

of priming experimental protocol of cell viability and quantitative data of cell viability of primed HepG2 and Hep3B cells. Data are
presented as mean ± SD. N = 5. (B) Schematic illustration of priming experimental protocol of cell invasion and quantitative data of cell
invasion of primed HepG2 and Hep3B cells. Values are expressed in mean ± SEM. N = 3. #P < 0.05, *P < 0.001.
www.oncotarget.com

191

Oncotarget

were superior to mesenchymal stem cell exosomes in
mitigating chemotherapy induced neurotoxicity and in
enhancing antineoplastic drug activity (data not shown).
Although miRNA-214 has been shown to target p53 in
breast cancer [60], this is not likely the mechanism by
which hCEC-Exo-214 exert their effect in HCC. hCECExo-214 significantly increased anti-cancer drug activity
in both HepG2 and Hep3B cell lines. However, HepG2
cells are p53 wildtype allele, whereas Hep3B cells are p53
null allele [63]. Instead, this study suggests that hCECExo-214 target P-gp and SF3B3. Western blot analysis
showed significant reduction in protein levels of both

P-gp and SF3B3, two genes directly or indirectly targeted
by miR-214 (Figure 5). Both genes have been reported
to be involved in cancer progression. P-gp mediates
chemoresistance in HCC [27, 64]. Increased expression of
P-gp was observed in HCC cells resistant to 5-fluorouracil
and epirubicin, as well as sorafenib [65, 66]. Reducing
P-gp using antisense RNA attenuates doxorubicin
resistance in HepG2 cells [67], whereas increased P-gp
levels substantially reduces sorafenib efficacy in HCC
cells [68]. SF3B3 is a pro-oncogene in renal cancer and
knockdown of SF3B3 in renal cancer cells significantly
inhibits tumor growth in tumor-bearing mice [69]. SF3B3

Figure 5: The effect of hCEC-Exo-214 in combination with anti-cancer drugs on P-gp and SF3B3 in HCC cells. (A and

B) Representative Western blot images and quantitative data of protein levels of P-gp (A) and SF3B3 (B) in HepG2 and Hep3B cells 2
days after treatment. Blot images of sorafenib treatment set were combined with no drug and oxaliplatin treatment set. Western blot band
intensity was quantified by using ImageJ with normalization to GAPDH. Values are expressed in mean ± SEM. N = 3. (C) Dual-luciferase
activity assay. Putative miR-214-3p target sequence of SF3B3 3′-UTR region were listed. WT: wildtype. mut: mutant. Assay was performed
in HepG2 cells. NC: negative control. Values are normalized and are presented in mean ± SEM. N = 3 individual experiments.
www.oncotarget.com
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also regulates enhancer of zeste 2 polycomb repressive
complex 2 subunit (EZH2) that promotes HCC progression
[70, 71]. EZH2 is one of the genes directly targeted by
miR-214 and overexpression of miR-214 reduces EZH2
protein levels [14]. Thus, reduction of P-gp and SF3B3
by hCEC-Exo-214 is likely to amplify the effect of anticancer drugs on HCC cells. Clearly a single miRNA
targets numerous mRNAs and an individual mRNA can be
targeted by several miRNAs [12, 72]. In addition to miR214, exosomal cargo contains other miRNAs, proteins and
lipids and their roles in mediating the therapeutic effects of
the combination therapy cannot be excluded and warrant
further investigation.
In summary, our data demonstrate that engineered
hCEC-Exo-214 significantly enhance the efficacy of
oxaliplatin and sorafenib anti-cancer drugs in HCC. The
findings support a potential clinical strategy of combining
engineered hCEC-derived exosomes with anti-cancer
agents to improve medical therapy in HCC.

ml streptomycin, and 100 μg/ml amphotericin (Invitrogen,
Waltham, MA, USA). Cell cultures were maintained in 75
cm2 flasks and kept in a humidified atmosphere with 5%
CO2 at 37°C.
Primary human cerebral endothelial cells (hCEC)
(Primary Human Brain Microvascular Endothelial Cells
ACBRI 376) were purchased from Cell Systems. The
cell culture was maintained using Cell System complete
classic medium (4Z0-500) with CultureBoost according
to the manufacturer’s protocol.
Liver tumor and adjacent non-tumor tissues were
acquired from patients with HCC and liver tumor undergoing
liver resection or transplant and the collected tissues were
kept in Eagle’s Minimum Essential Medium (EMEM) at 4°C.
Under aseptic conditions, the connective tissues, bile ducts,
and blood vessels were trimmed away as much as possible.
Tumor tissues were then minced into approximate 1 mm
pieces and incubated in 6-well plates coated with attachment
factor (Cell Systems: 4Z0-210) in EMEM medium 10%
fetal bovine serum (FBS) and 1% of anti-anti (Invitrogen).
Plates were kept in a humidified atmosphere with 5% CO2 at
37°C for 2–3 days to allow attachment. Media was changed
regularly, and cells were passed at 80–90% confluency. All
experiments were done within 5–10 cell passages.

MATERIALS AND METHODS
Patients and tissues
Patient tissues used in the present study were
obtained from patients with hepatocellular carcinoma or
hepatocellular adenoma who underwent liver resection
or liver transplant at Henry Ford Hospital (Detroit,
MI, USA). The study was approved by the Henry Ford
Health System (HFHS) Institutional Review Board (IRB
No.12996). The IRB grants a waiver of the requirements to
obtain informed consent. All experiments were performed
in accordance with relevant guidelines and regulations.

Transfection of miR-214 into hCEC cells
The human pre-microRNA expression construct
Lenti-miR-214 (PMIRH214PA-1) was purchased from
System Biosciences. Briefly, 5 × 105 hCECs were
suspended in 100 μl of Ingenio Electroporation Solution
(Mirus Bio LLC., Madison, WI, USA) with 3 μg of
plasmid DNA. Program U11 was used for electroporation
in an Amaxa Nucleofector Device (Lonza Group Ltd.,
Walkersville, MD, USA). Transfected hCECs were resuspended in 10 ml complete culture medium, followed
by centrifugation at 500× g, and then cultured for exosome
production. 1 × 106 hCECs were seeded in 10 ml complete
classic medium (4Z0-500, Cell Systems, Kirkland, WA,
USA) and cultured for 48 hr. The culture medium was
then replaced with serum free medium (4Z3-500, Cell
Systems, Kirkland, WA, USA), and cells were cultured
for an additional 48 hr when engineered exosomes were
collected for analysis and experiments.

Anti-cancer drugs
Oxaliplatin was purchased from Sigma & Aldrich
(St. Louis, MO, USA) and was dissolved in dimethyl
sulfoxide (DMSO) to make stock solution at 25 mM.
Sorafenib was purchased from Santa Cruz Biotechnology
(Dallas, TX, USA), and was dissolved in dimethyl
sulfoxide (DMSO) to make stock solution at 100 mM.
The stock solutions were further diluted to appropriate
concentrations with cell culture medium immediately prior
to experiments. DMSO was used as a control.

Cell culture

Isolation and characterization of exosomes from
naïve and engineered hCECs

Hepatocellular carcinoma cell lines HepG2 (ATCC®
HB-8065™), Hep3B (ATCC® HB-8064™), and the
human liver epithelial cell line THLE-2 (ATCC® CRL2706™) were purchased from American Type Culture
Collection (ATCC, Rockville, MD) and were cultured in
Eagle’s Minimum Essential Medium (EMEM; ATCC).
All cell lines were maintained in EMEM containing 10%
fetal bovine serum (FBS), 100 units/ml penicillin, 50 μg/

Exosomes derived from hCECs or miR-214
transfected hCECs were isolated from the supernatant of
CECs cultured in exosome free medium according to our
published protocol [73]. Briefly, the culture medium of
hCECs was collected after a 48~72 h incubation period
according to time required to reach 80% confluence,
followed by centrifugation at 2,000 rpm for 5 min. The
supernatant of the spin down was filtered through 0.22 µm
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filter (Millipore, CA, USA) to remove dead and large cell
debris. The flow through was then centrifuged at 100,000Xg
for 2 hours. The pellet was dissolved in 200 μl sterilized
PBS, and the supernatant was collected as a negative control.
The particle numbers and size of harvested hCEC-exosomes
were analyzed by Nanoparticle Tracking Analysis (NTA)
system (IZON, UK). Transmission electron microscope
(TEM) and Western blot analysis were performed to
characterize hCEC-exosomes [74]. Total proteins from
hCEC-exosomes were collected using 2X lysis buffer (RIPA,
Sigma) supplemented with Protease Inhibitor Cocktails set
I (100X) (MilliporeSigma, Burlington, MA, USA) followed
by Western Blot analysis of exosomal marker proteins.

ice cold PBS followed by extraction in 500 μl RIPA lysis
buffer (Life Technologies, Carlsbad, CA, USA). Equal
amounts of proteins, as determined by the BCA protocol
(Pierce, Rockford, IL, USA), were run on 10% TrisGlycine gels (Invitrogen) and then transferred to PVDF
membranes (Whatman). The membranes were blocked
with 0.1% I-Block (Applied Biosystems, Foster, CA,
USA) in PBS-T (0.1% Tween-20), followed by incubation
with primary antibodies against P-gp (ab170904, Abcam),
MRP2 (R260, Cell Signaling), SF3B3 (ab209402,
Abcam), GAPDH (ab9484, Abcam), CD9 (ab92726,
Abcam), CD63 (ab134045, Abcam), and Alix (3A9, Cell
Signaling). Bands were detected using SuperSignal West
Pico chemiluminescent protein detection kits (Pierce). Each
experiment was repeated three times. The densities of the
bands were analyzed using ImageJ software.

MTT (3-(4,5-dimethylthiazol-2-yl)-2,5
diplenyltetrazolium bromide) assay

Isolation of total RNA and quantitative reverse
transcribed-PCR

To measure cell viability, cells were seeded in
96-well plates at a density of 800 cells per well. After
overnight incubation, culture medium was removed, and
cells were rinsed with PBS and incubated in complete
medium with indicated treatment. After 5 days of treatment,
medium was removed and MTT was added to each well
with an additional 4 hr incubation to allow mitochondrial
dehydrogenase to convert MTT into insoluble formazan
crystals. The medium was then aspirated, and formazan
solubilized by adding 150 μl of DMSO. The absorption of
solubilized formazan was measured at a wavelength of 490
nm by an ELISA plate reader (EL340 microplate reader;
Bio-Tek Instruments, Winooske, VT, USA).

After 2 days of treatment, HepG2 and Hep3B cells
were lysed in Qiazol reagent, and the total RNA was isolated
using miRNeasy Mini kits (Qiagen, Valencia, CA, USA).
miRNA was stem-loop reverse transcribed (RT) with the
miRNA Reverse Transcription kit (Applied Biosystems) and
real-time PCR amplification was performed with the TaqMan
miRNA assay (Cat# 4427975, Applied Biosystems), which is
specific for mature miRNA sequences. U6 snRNA was used
as the internal control for TaqMan miRNA assay to detect the
expression level changes of miR-214 in cells. Primers used
for miR-214-3p (Assay ID: 002306), miR-92-3p (Assay ID:
000431), U6 (Assay ID: 001973).

Invasion assay
Invasion assay was performed according to our
published protocol with modification [75]. Specifically,
24-well Plate invasion chambers were pre-coated with
Matrigel (Corning, Corning, NY, USA). HepG2 or
Hep3B cells (5 × 104), after receiving indicated treatment
for 2 days, were re-suspended in 0.5 ml of serumfree medium and loaded to the upper chamber while
the lower chamber was filled with 0.5 ml of complete
medium containing FBS, which served as a chemoattractant. After 16 hr of incubation at 37°C, cell ability
to penetrate the extracellular matrix (ECM) was assessed
by staining the cells on the lower surface of the membrane
with CellTracker™ Green (Molecular Probes, Eugene,
OR, USA). Four fields of cells were counted randomly
in each well under a fluorescent microscope at 200×
magnification. Data are normalized to control treatment,
which is set as 1, and are expressed as mean ± SEM of
three independent experiments.

Dual-luciferase activity assay

Western blot analysis

Statistical analysis

HepG2 and Hep3B cells (5 × 105 cells) were seeded
in T25 flasks. One day after seeding, cells were subjected
to indicated treatment for 48 hr. Cells were rinsed with

Data are presented as mean and standard error.
Statistical significance was analyzed by Student T-test. P
value less than 0.05 (P < 0.05) was considered significant.
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Luciferase reporter assay was conducted according
to previous report [76]. Briefly, HepG2 cells were cultured
in 6-well plates and co-transfected with 3 µmol of pMIRREPORT (Applied Biosystems) containing either SF3B33′UTR-WT or SF3B3-3′UTR-mut, 30 pmol of miR-214-3p
mimics (Cat#:4464066. ThermoFisher Scientific, Waltham,
MA) or negative control (Cat#:4464058), and 1µmol of
pRL-TK (Promega, Madison, WI, USA) containing
Renilla luciferase per well. Transfection was performed
by means of Lipofectamine 2000 (Invitrogen) and OptiMEM I reduced serum medium (Invitrogen). Three days
after transfection, firefly and Renilla luciferase activity was
analyzed by using the Dual-Luciferase Reporter Assay kit
(Promega) and plate reader (Perkin Elmer, Waltham, MA,
USA). Data were presented as relative luciferase activity.
Three independent experiments were performed.
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